Nicholas Kenny, PhD
Senior Vice President, Oncology
 Dr. Kenny has 25 years of research and development experience. Dr. Kenny’s industry career began as a Clinical Research Fellow. He moved into management roles within the CRO industry, where he was responsible for establishing the strategic direction of clinical programs, as well as having global oversight of project management, clinical monitoring, and regulatory staff. He has provided clinical development and regulatory strategy consulting services, international project management, and process development and integration expertise to a variety of pharmaceutical and biotech companies. Over the past 10 years Dr. Kenny’s drug development expertise has been primarily focused upon oncology clinical development.
Prior to his move to industry, Dr. Kenny spent 15 years in endocrinology and cell biology research and teaching in the United Kingdom, Canada, and the United States (US) where he was Assistant Professor in the College of Medicine at the University of Vermont. He was also a National Institute of Health Research Fellow at McGill University and received his PhD in Reproductive Endocrinology from the University of Hull, United Kingdom.
Scott Williams, MD
Vice President, Oncology
 Dr. Williams has more than 20 years of clinical surgical oncology experience in a university medical center setting. He has worked in the CRO industry for over 5 years and has experience in many areas of clinical research, including protocol development, site selection, team training, and medical safety management. Dr. Williams’ list of accomplishments includes a surgical oncology fellowship at Memorial Sloan-Kettering Cancer Center where he studied under Willet Whitmore, the first oncologic surgeon at the University of Pittsburgh. Here he performed many urologic procedures prior to the arrival of urologic oncologists. Dr. Williams has also been very active in the National Surgical Adjuvant Breast and Bowel Project (NSABP) and the Eastern Cooperative Oncology Group (ECOG). He has served as Chief of Surgery at Letterman Army Medical Center and Magee Women’s Hospital, and has served as Associate Professor and Professor of Surgery at the University of Pittsburgh Medical Center.
Constance K. Wierman
Vice President
 Ms. Wierman joined INC Research in 2005. She has nearly 25 years of experience in the biopharmaceutical industry, inclusive of 10 years specific to the CRO sector. She has held positions of increasing responsibility within the CRO environment, with an emphasis on clinical development of oncology therapies on a global basis. Her experience includes a breadth of key business support positions in the medical device and pharmaceutical sectors of healthcare. She started her career in marketing of Class 3 medical devices for St. Jude Medical, Inc and Baxter HealthCare, then moved into pharmaceutics for Fujisawa; she has significant product launch experience in both sectors. She also has business development experience in the service sector, building a business base among biotechnology and pharmaceutical companies in the oncology arena for ILEX Oncology, Inc. Prior to joining INC, Ms. Wierman was responsible for developing and leading a team of Medical Science Liaisons in the United States for ILEX (now Genzyme) to support the research and educational goals for use of oncology agents under development and newly launched.
Prior to her move to industry, Ms. Wierman had six years bench research experience in academia including pharmaceutical biochemistry and medical chemistry.
J. Michael Hamilton, M.D.
Senior Medical Director, Oncology
 Dr. Hamilton has more than 25 years of experience in clinical oncology and hematology-oncology drug development. During 17 years at the National Cancer Institute, he oversaw clinical strategy in colorectal cancer and CNS tumors in the Cooperative Group system. In this setting he also conducted Phase I clinical trials with new agents, including anti-tumor vaccines, and fulfilled duties as chairman of the NCI Institutional Review Board, director of the Oncology Fellowship Training Program, and supervisor of the hematology-oncology research nurses, outpatient clinic, and in-patient oncology unit at the National Naval Medical Center.
Subsequently, for seven years at GlaxoSmithKline (GSK), he was the medical director for the FDA approval and late phase development of BEXXAR and the early development, leading to the FDA approval of Promacta (eltrombopag) as well as the development of other hematology-oncology compounds and vaccines. After leaving GSK, Dr. Hamilton served as the chief medical officer (CMO) at Avalon Pharmaceuticals where he oversaw all clinical strategic planning and development of discovery and clinical projects, as well as evaluation and ranking of licensing opportunities. Dr. Hamilton continues to teach patient care and clinical oncology to NCI Fellows at the National Naval Medical Center in Bethesda, MD.
Michael Kurman, M.D.
Senior Medical Director, Oncology
 Dr. Kurman has 30 years of oncology drug development experience as both a clinical investigator and pharmaceutical executive. Dr. Kurman started his career in the practice of oncology, during which he was an investigator on several oncology clinical trials. Since joining industry, he has held positions of progressively more responsibility in Janssen, Cytogen and US Bioscience, and was involved in the successful development or launch of four oncology products. Before joining INC Research, Dr. Kurman was Vice President of Clinical Operations for Quintiles’ Oncology Division.
His primary interests are in early phase oncology clinical trial design and drug development, and in strategic portfolio management. In addition, he serves on the Scientific Advisory Boards of several companies and is on the Board of Directors of Thallion Pharmaceuticals. Dr. Kurman is board certified in Internal Medicine and Oncology, and did his oncology training at Mt. Sinai Hospital in New York.
|
Case Studies
Oncology: Prostate Cancer Study
Pain: Oncology Pain
Oncology: Phase I Studies
Oncology: Phase II Hematology Study
Oncology: Phase IIIb Global Study
Leadership
Nicholas Kenny, PhD
Senior Vice President, Oncology
Scott Williams, MD
Vice President, Oncology
Constance K. Wierman
Vice President
J. Michael Hamilton, MD
Senior Medical Director, Oncology
Michael Kurman, MD
Senior Medical Director, Oncology
|
